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Background: Melatonin, a hormone-like substance involved in the regulation of the circadian rhythm, has been
demonstrated to protect cells against oxidative DNA damage and to inhibit tumorigenesis.
Results: In the current study, we investigated the effect of melatonin on DNA strand breaks using the alkaline DNA
comet assay in breast cancer (MCF-7) and colon cancer (HCT-15) cell lines. Our results demonstrated that cells
pretreated with melatonin had significantly shorter Olive tail moments compared to non-melatonin treated cells
upon mutagen (methyl methanesulfonate, MMS) exposure, indicating an increased DNA repair capacity after
melatonin treatment. We further examined the genome-wide gene expression in melatonin pretreated MCF-7 cells
upon carcinogen exposure and detected altered expression of many genes involved in multiple DNA damage
responsive pathways. Genes exhibiting altered expression were further analyzed for functional interrelatedness
using network- and pathway-based bioinformatics analysis. The top functional network was defined as having
relevance for “DNA Replication, Recombination, and Repair, Gene Expression, [and] Cancer”.
Conclusions: These findings suggest that melatonin may enhance DNA repair capacity by affecting several key
genes involved in DNA damage responsive pathways.
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Melatonin (MLT), a hormone secreted by the pineal
gland, plays an important role not only in the regulation
of the circadian rhythm but also in the modulation of
cancer risk by acting as an anti-inflammatory agent and
an antioxidant (reviewed in [1,2]). Recent epidemiologic
evidence have pointed to an inverse relationship between
night shift work and melatonin levels [3], which provides
a possible explanation for the observation of increased
breast cancer risk among female shift workers [4,5].
By the same token, significantly decreased plasma
melatonin levels have been found in patients with
endometrial cancer [6,7]. In animal studies, melatonin
has been shown to inhibit the development of spon-
taneous and chemically induced mammary carcino-
genesis [8], colon and hepato-carcinogenesis, [9], and* Correspondence: yong.zhu@yale.edu
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reproduction in any medium, provided the orcarcinogenesis of soft tissue, the lung, the uterine cervix
and the vagina [10-13].
In vitro functional analyses using cancer cell lines such
as MCF-7 have been performed to investigate the effects
of melatonin on cell growth, DNA synthesis, cell cycle,
and apoptosis [14-17]. These studies have shown that
melatonin may reduce MCF-7 cell proliferation by modu-
lating cell-cycle kinetics, DNA synthesis, and apoptotic
processes. Other studies have further demonstrated that
melatonin can inhibit fatty acid growth-factor uptake [18]
and telomerase activity in cancer cells [19]. The role of
melatonin in DNA repair pathways was also recently
documented in a study that showed a protective role for
melatonin against oxidative DNA damage [20].
However, the impact of melatonin on DNA repair cap-
acity for DNA strand breaks, the most common type of
DNA damage, has not been previously examined using
the comet assay, a reliable method for detecting and
measuring DNA damage and DNA repair capacity [21].
Moreover, little is known about how melatonin affectsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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response. In the current study, we performed both a comet
assay and genome-wide expression assay using breast
cancer cells (MCF-7) and colon cancer cells (HCT-15) to
investigate the impact of physiological concentrations of
melatonin on DNA repair capacity and expression of genes
in DNA damage responsive pathways.
Methods
Cell culture and treatments
MCF-7, a human breast cancer cell line, and HCT-15, a
human colon cancer cell line, were purchased from the
American Type Culture Collection (ATCC, Manassas, VA ).
MCF-7 cells were maintained as monolayer cultures in 25
cm2 polystyrene culture flasks (Falcon, Becton Dickinson
BioScience, Le Pont de Claix, France) in Dulbecco's
Modified Eagle's Medium (DMEM) supplemented with 10%
fetal bovine serum, 1% penicillin-streptomycin (Invitrogen,
Carlsbad, CA) and 0.01mg/ml insulin (Sigma-Aldrich, St.
Louis, MO). HCT-15 cells were maintained in Roswell Park
Memorial Institute (RPMI) 1640 media supplemented with
10% fetal bovine serum and 1% penicillin-streptomycin.
Cells were incubated at 37°C in a humid atmosphere
containing 5% CO2 and subcultured every 3~4 days.
Before each experiment, stock subconfluent mono-
layers of MCF-7 or HCT-15 cells were incubated with
0.25% trypsin-EDTA at 37°C for 3~5 min. MCF-7 cells
were then resuspended in DMEM supplemented with
10% FBS and 0.01mg/ml insulin and HCT-15 cells were
resuspended in RPMI 1640 media supplemented with
10% fetal bovine serum. Cell number and viability were
determined by staining a small volume of cell suspension
with 0.4% trypan blue saline solution and examining the
cells in a hemocytometer. For all assays, MCF-7 cells
were seeded at a density of 3~5×105 cells/ml in DMEM
supplemented with 10% FBS, 0.01mg/ml insulin, and 1%
penicillin-streptomycin for 24 hr (37°C, 5% CO2), and
HCT-15 cells were seeded in RPMI 1640 supplemented
with 10% FBS. After 24 hours, the media were replaced
with fresh media containing either 1 nM melatonin
(Sigma Chemical Co., St Louis, MO, USA), or the diluent
(ethanol, final concentration 0.000005%) and cells were
incubated for another 24 hours. Methyl methanesulfonate
(MMS, mutagenic agent) (0.0125%, v/v, Sigma Chemical
Co., St Louis, MO, USA) or PBS was added to the culture
medium for an 1-hour treatment followed by an extra
3-hour recovery time in fresh medium. Cells were then
harvested for the comet assay and RNA extraction.
Comet assay
DNA damage was assessed through the use of a comet
assay that was first described by Östling & Johanson [22]
and later improved by Singh et al. [23]. Following MLT
and MMS/PBS treatment as described above, cells wereharvested and mixed with 0.5% low-melting agarose [24]
and fixed onto frosted slides pre-coated with 1.0%
normal melting agarose (NMA). The slides were
immersed in cold, freshly made lysing solution in the
dark at 4°C for at least 1 hr and then rinsed with
neutralization buffer to remove detergents and salts.
Slides were then placed in a horizontal electrophoresis
device at 4°C in alkaline buffer (pH>13) for 30 min to allow
for DNA unwinding and expression of alkali-labile damage,
followed by electrophoresis for 30 min (25V, 300mA),
which allows damaged and/or broken DNA to migrate
away from the nucleus. After electrophoresis, the slides
were washed three times with a neutralization buffer. Slides
were then stained with ethidium bromide (10 μg/ml),
visualized by fluorescence microscopy, and analyzed using
the Komet 5.0 comet assay analysis software which quanti-
tatively determines the extent of DNA damage in each
sample using the mean Olive tail moment calculation as
previously described [25]. The head of the comet image
consists of intact DNA, while the tail material is comprised
of damaged DNA. Longer “tails” are associated with a
greater accumulation of damage. Olive tail moment is
defined as the function of the tail length and the precentage
of DNA in the tail. Olive tail moment = (Tail.mean-Head.
mean) X Tail%DNA/100. The mean Olive tail moment was
determined for 200 cells (two slides with 100 cells per slide)
from each of the four treatment groups (MLT, MLT+MMS,
MMS, and Control) and all pairwise comparisons were
examined using Fisher’s PLSD.
Genome-wide expression microarray analysis
Genome-wide expression array analysis was only performed
following MLT+MMS and MMS treatments. MCF-7 cells
were harvested and total RNA was isolated using the
RNeasy Mini Kit (Qiagen, Valencia, CA), with on-column
DNA digestion, according to the manufacturer’s instruc-
tions for mammalian cells. Genome-wide expression differ-
ences among MLT/MMS and diluents/MMS treated cells
were determined by using the HumanHT-12 v4 Expression
BeadChip, Illumina's latest whole-genome expression array
system (Illumina, San Diego, CA). Samples were run in bio-
logical duplicate. Array hybridization and signal scans were
performed by Yale University’s W.M. Keck Foundation
Biotechnology Research Laboratory. The images were ana-
lyzed using the Beadstudio software. Quality control and
data analysis were carried out according to the instructions
provided by Illumina. All array data have been uploaded to
the Gene Expression Omnibus (GEO) database, and can be
accessed via their website (http://www.ncbi.nlm.nih.gov/
geo/; accession number pending).
Pathway-based network analysis
The set of differentially expressed transcripts was inves-



























Figure 1 DNA damage repair capacity as assessed by the Comet Assay. (A) Representative cell images from each of the four treatment
groups using MCF-7 cells. (B) Mean Olive tail moment determined from each of the four treatment groups using HCT-15 and MCF-7 cells. Among
the samples not treated with mutagen, the difference in tail moment between cells in the control group and MLT-treated group was not
significant in both cell lines (p=0.976 for MCF-7, p=0.928 for HCT-15). However, among the mutagen-treated populations, cells with MLT
pretreatment had a significantly shorter mean Olive tail moment (p<0.0001 in both cell lines) compared to cells without MLT pretreatment. The
error bar corresponds to mean±SD.
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changes in gene expression were determined with the
normalized signal intensities of probes from MLT+MMS
treatment divided by the signal intensities from MMS
treatment. The set of differentially expressed genes and
their fold change values were inputted into the IPA pro-
gram and used to identify interaction models of genesusing the Ingenuity Knowledge Base, a manually curated
database of functional interactions extracted from
peer-reviewed publications (http://www.ingenuity.com). A
Fisher’s exact test based on the hypergeometric distribution
was then done for each identified network to determine
the likelihood of obtaining at least the same number of
interrelated molecules by chance.
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Statistical analysis of DNA damage repair capacity was
performed using the Komet 5.0 comet assay analysis
software. Differences in DNA repair were determined
for all pairwise associations of the four treatment groups
(MLT, MLT+MMS, MMS, and Control) using ANOVA
Fisher’s PLSD for the mean Olive tail moment with the
SAS statistical software package, version 9.1 (SAS Institute,
Cary, NC). The Student’s t-test was performed to compare
gene expression levels using normalized expression values
from the Illumina expression array for the MLT+MMS and
MMS treatment groups. Transcripts were identified as sig-
nificantly influenced by MLT treatment if their expression
differences fit the criteria of p<0.05.Results
To study the impact of melatonin on DNA repair
capacity for MMS-induced strand breaks, the comet
assay was used to assess the differences in DNA damage
accumulation and repair capacity among four treatment
groups (MLT, MLT+MMS, MMS, and Control). Figure 1A
shows a representative comet assay image from each treat-
ment group using MCF-7 cells, and Figure 1B depicts the
mean Olive tail moment for each group in MCF-7 and
HCT-15 cells. For MCF-7 cells, the mean Olive tail
moments were 0.18±0.10 for the control group, 0.22±0.10
for the MLT treatment group, 11.66±6.51 for MLT+MMS,
and 24.13±13.12 for MMS only. For HCT-15, the Olive tail
moments were 0.97±0.52 for the control group, 0.86±0.50Table 1 Functions and molecules in the top 5 networks of ide
Network Score Focus molecules Top functions
I 34 16 DNA Replication, Recombination, and
Repair, Gene Expression, Cancer
II 31 15 Cell-to-Cell Signaling and Interaction,
Cellular Movement, Tissue Developme
III 28 14 Cell-mediated Immune Response,
Cellular Movement, Hematological
System Development and Function
IV 28 14 Lipid Metabolism, Small Molecule
Biochemistry, Cardiovascular System
Development and Function
V 23 12 Cell Death, Cellular Development,
Cellular Growth and Proliferation,for the MLT treatment group, 10.80±5.65 for MLT+MMS,
and 29.51±16.10 for MMS only.
Among the samples not treated with mutagen, the
differences in mean Olive tail moments between cells in
the control group and those in the MLT treatment
group were not statistically significant for either cell line
(p=0.976 for MCF-7, p=0.928 for HCT-15), indicating
that without inducing damage, there is no difference in
detected DNA damage levels. However, among the
mutagen-treated populations, cells with MLT pretreat-
ment had a significantly shorter mean Olive tail moment
(p<0.0001 in both cell lines), as depicted in Figure 1B,
indicating increased DNA repair capacity compared to
cells without MLT pretreatment.
To further investigate possible mechanisms of the
observed protective effect of MLT on DNA repair capacity
induced by mutagen exposure, we performed a genome-
wide expression microarray analysis. The identified tran-
scripts affected by MLT upon MMS exposure were
investigated for functional interrelatedness using the IPA
software. There were 104 genes identified from the ex-
pression microarray analysis, as shown in Additional file
1: Table S1. A list of the top 5 networks significantly asso-
ciated with the set of input genes is displayed in Table 1.
The network most significantly associated with the set of
altered genes was defined as having relevance for “DNA
Replication, Recombination, and Repair, Gene Expression,
[and] Cancer” (Score=34, Figure 2).
This network consists of 36 genes, 16 of which exhibited
altered expression following MLT treatment (ARHGAP6,ntified genes regulated by MLT
Molecules in network
ARHGAP6, C15orf23, C2CD2, C2CD4B, CCNB2, CEP63, CEP152, CR2,
DCAF11, DYNLL2, GTF2IRD2B, HNRNPD, INTS2, MCART1, miR-183,
miR-548f/miR-548a-3p, N4BP2L2, NEIL1, PARP11, PCNA, PCYT1B,
POLB, PRDX6, RBM47*, SPAG5, SPRY2, TET1, THEM5, TRAPPC1, UBE2,
UBE2A, UBE2G2, WRN, XRCC1, ZNF264/ZNF805
nt
ADARB1, APPBP2, ASAP2, CADM1, CRYBA2, DENND1A, FAM96A, FRK,
GLDN, KIAA0907, LYPD1, MAP3K13, miR-450, miR-873, miR-450b-5p,
miR-520d-5p/miR-524-5p, miR-548p, MUL1, NFASC, NPTN, PCSK5,
PDE6D, RAD54B, RBM47*, SDHAF2, SHB, SLC16A9, STK10, TBL2,
TCEB3, TET1, THSD7A, TMOD2, UBE2Q2, ZNF430
Acan, ALOX12, ANKLE2, C2orf27A/C2orf27B, CCDC90A, CDC42,
CDK5RAP2, CILP2, CLEC2D, CMA1, CST3, CTSH, EIF5A, FN1, HP, IFI27,
IL13, IL11RA, ITGAE, LLGL2, miR-29b/miR-29c/miR-29a, PLUNC,
RABGGTB, RCC2, RPL5, RPL23, SFTPB, SLC23A2, SOCS5, SPAG4, STAT3,
TGFB1, tretinoin, WDR92
ATP, C17orf90, C1orf123, Ca2+, CCDC90B, DCAF11, DMC1, FPGS,
FXYD6, G protein alphai, GABRP1, GBP3, GPSM1, GRB14, GTP,
HIST1H2AH, HIST2H2AA3/HIST2H2AA4, HNF4A, miR-125a-3p,
miR-1267/miR-582-3p, MRPS12, NOP16, P2RX2, P2RX3, P2RX5, P2RX6,
PLCB3, PRDX5, PTK6, RGL2, RPL30, RPL18A, RTCD1, TAC3, THAP4
26s Proteasome, Akt, BEX2, BRAP, CLIP2, CXCL3, DYRK1B, ERBB3,
ERK1/2, FER, HERP, HEY1, HRAS, IDE, IL17R, IL36A, Insulin, LDL, Mapk,
miR-205, NFkB, Oas1h, Olfr1508, P38 MAPK, Pdgf, PDPK1, PI3K, Pvr,
Rasgrf, RGS3, RPS6KA, SIRT4, TUBB, UTS2
Figure 2 The top network, “DNA Replication, Recombination, and Repair, Gene Expression, Cancer”, formed by genes exhibiting
altered expression in MLT-pretreated MCF-7 cells upon MMS exposure relative to untreated MMS-exposed cells. Upregulated transcripts
are shaded in red, while downregulated transcripts are shaded in green, with color intensity signifying the magnitude of fold change. Each
interaction is supported by at least one literature reference identified in the Ingenuity Pathway Knowledge Base, with solid lines representing
direct interactions, and dashed lines representing indirect interactions.
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http://www.biomedcentral.com/1471-2121/14/1C2CD2, C2CD4B, CEP152, GTF2IRD2B, INTS2, MCART1,
N4BP2L2, NEIL1, PARP11, RBM47, TET1, THEM5,
TRAPPC1, UBE2A and ZNF264/ZNF805). Among these
genes are several with known roles in the regulation of
DNA repair activity, including CEP152, a regulator ofgenomic integrity and cellular response to DNA damage
through the ATR-mediated checkpoint signaling pathway
[26]. Our results indicate that CEP152 expression was sig-
nificantly upregulated following MLT treatment. Similarly,
N4BP2L2 was induced after MMS exposure and higher
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http://www.biomedcentral.com/1471-2121/14/1N4BP2L2 expression was detected in MLT pretreated cells
upon MMS exposure. N4BP2L2, which encodes a phospho-
noformate immuno-associated protein, is phosphorylated
by ATM or ATR upon DNA damage.
Many other pathways relevant to DNA repair were
also identified. As illustrated in Figure 3, genes directly
or indirectly influenced by MLT are involved in multiple
signaling pathways associated with DNA repair, including
IGF1 signaling, EIF2 signaling, JAK/Stat signaling, PI3K/
AKT signaling, and P70S6K signaling.
Discussion
The protective role of melatonin in DNA damage
response observed in our study is congruent with previous
findings. Since melatonin was initially identified as a free
radical scavenger in 1993, many studies have shown that
melatonin may protect DNA against free radical damage
[27-31] by stimulating antioxidative enzymes and scaven-
ging •OH radicals [32,33]. In addition to stimulating DNA
repair capacity, melatonin may aid in inactivating the
DNA-damaging agent [34]. However, most previous studies
have focused their investigation on the role of melatonin in
protecting the cell against oxidative DNA damage. Our
results demonstrate for the first time that melatonin may
also increase DNA repair capacity against strand breaks
caused by the DNA damaging agent MMS in vitro, as
measured by the comet assay.
Although increasing evidence suggests a protective role
of melatonin in the DNA repair pathway, the molecular
mechanism of melatonin is still unclear, especially with
regard to the potential impact of melatonin on the
expression of DNA damage responsive genes. Our current
study examined genome-wide gene expression affected by
MLT upon MMS-induced DNA damage and found that
melatonin can affect multiple DNA damage responsive
pathways that are involved in several signaling pathways
associated with DNA damage.Figure 3 Pathways related to genes affected by MLT treatment. These
as being significantly associated with the set of genes with altered expressUpregulation of CEP152 and N4BP2L2 associated with
MLT pre-treatment in our study showed positive activation
of DNA repair capacity. CEP152 is a centrosomal protein
involved in the maintenance of genomic integrity and
response to DNA damage, acting as a scaffold facilitating
the recruitment of PLK4 and CPAP to the centrosome to
ensure a faithful centrosome duplication process [24,34].
Increased CEP152 expression may facilitate DNA damage
checkpoint control and ATR/ATM-mediated phosphoryl-
ation in response to accumulation of DNA damage
[26,35,36].
It has been suggested that N4BP2L2 is phosphorylated at
serine 199 as a substrate of the protein kinases ATM and
ATR in response to DNA damage [37]. ATR is known to
be involved mainly in responses to DNA single-strand
breaks (SSBs), while ATM is activated in response to DNA
double-strand breaks (DSBs). Since ATM and ATR both
trigger an overlapping set of cellular responses that pro-
mote cell cycle arrest and DNA repair [38], it is suggested
that MLT may activate multiple DNA repair processes
through the increase of N4BP2L2 expression and induction
of ATR/ATM-mediated damage responsive pathways.
While our data support melatonin's protective role in
DNA strand breaks and illuminate potential molecular
pathways by which this role is fulfilled, without the
inclusion of additional experimental evidence, our
conclusions remain quite exploratory. Future investigations
should therefore make use of alternative strand break
visualization technologies, including phospho-H2AX label-
ing, to provide confirmational evidence, assess the kinetics
of MLT's effect on DNA repair, and measure the response
in specific biological pathways to MLT induction at the
protein level.
Conclusion
Our data support the hypothesis that melatonin may
enhance DNA repair capacity and play a protective role inpathways were identified by the Ingenuity Pathway Analysis software
ion as a result of MLT treatment.
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http://www.biomedcentral.com/1471-2121/14/1cancer development. Although the molecular mechanisms
of melatonin in cancer-related biological pathways are still
largely unknown, our data suggest that melatonin may
participate in the regulation of several key genes involved
in DNA damage repair pathways.
Additional file
Additional file 1: Table S1. Identified genes affected by melatonin
upon MMS-induced DNA damage.
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